II. Indications
III. Contraindications
- Live Vaccines (see Drug Interactions below)
IV. Mechanism
-
Janus Kinase (JAK) and the JAK/STAT Pathway
- Janus Kinase (JAK) is a family of intracellular Tyrosine Kinases that trigger a signaling cascade of Cytokines
- JAK acts on STAT transcription factors, triggering gene transcription related to inflammation
- Janus Kinase (JAK) is named for its Protein's 2 phosphate-Transferring domains
- Janus Kinase Inhibitor
- JAK Inhibitors are small molecule agents that interfere with Cytokine signalling by blocking their receptor binding
V. Medications
- Ruxolitinib or Jakafi (JAK1 and JAK2 Inhibitor)
- Indicated in Rheumatoid Arthritis and Myelofibrosis (including Polycythemia Vera)
-
Baricitinib or Olumiant (JAK1 and JAK2 inhibitor)
- Indicated in Rheumatoid Arthritis and Alopecia Areata
-
Upadacitinib or Rinvoq (JAK1 inhibitor)
- Indicated in Rheumatoid Arthritis
-
Tofacitinib or Xeljanz (JAK3 Inhibitor)
- Indicated in Rheumatoid Arthritis and Psoriatic Arthritis
VI. Adverse Effects
- Venous Thromboembolism
- Sudden cardiovascular death (associated with Tofacitinib)
- FDA black box warning for major cardiovascular event risk
-
Immunosuppression
- Tuberculosis reactivation risk (test for Latent Tb before starting)
- Increased risk of opportunistic infection (e.g. invasive fungal infections, Pneumonia, Shingles)
- Malignancy risk (e.g. Lymphoma)
VII. Drug Interactions
-
Live Vaccines
- Hold JAK Inhibitors for 1 week before and 4 weeks after Live Vaccines
VIII. References
- (2019) Presc Lett 26(10): 58